2012
London, UK, 11 December 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces the appointment of Richard Wohanka as a non-executive director of the Board, effective from 1...
London, UK, 20 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes the announcement by Janssen-Cilag International NV (Janssen) that the Committee for Medical Products for...
London, UK, 19 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces that full data from VANISH-1 and VANISH-2, the two US pivotal Phase III trials of polidocanol...
London, UK, 08 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim results for the six months ended 30 September 2012. Click here to down load the PDF
London, UK, 03 October 2012 BTG plc (LSE: BTG), the specialist healthcare company, provides the following update for the six months ended 30 September 2012 ahead of the planned publication of its...
London, UK, 17 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Andy Burrows, Director of Investor Relations will be presenting an overview of the company...
London, UK, 10 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Louise Makin, CEO will be presenting an overview of the company and its strategic...
West Conshohocken, PA, 05 September 2012 New Technology Add-on Payment provides up to 50% of the cost of Voraxaze®prescribed in the inpatient setting BTG International Inc., the specialist...
London, UK, 08 August 2012 BTG plc (LSE: BTG), announces top-line data from a global double-blind Phase IIb study comparing the efficacy and safety of two doses of AZD9773 (CytoFab™) with...
London, UK, 17 July 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim management statement for the period from 1 April 2012 to 16 July 2012. Trading within...
London, UK, 12 June 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes today’s announcement by Sanofi and its subsidiary Genzyme, relating to the submission of a supplemental...
West Conshohocken, PA, 04 June 2012 BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze®(glucarpidase) at the American Society of...
London, UK, 25 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York,...
London, UK, 21 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces its final results for the year ended 31 March 2012. Click here to download the PDF
West Conshohocken, PA, 30 April 2012 BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the...
London, UK, 23 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-1, the second and final US pivotal Phase III trial of Varisolve®...
London, UK, 04 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, provides the following update for the year ended 31 March 2012 ahead of the planned publication of its Final...
London, UK, 28 March 2012 Powder for solution for infusion Launched in the UK, BTG, the specialist healthcare company today announces the launch of DigiFab® in the UK through Protherics Medicines...
London, UK, 08 March 2012 Regulatory applications to be submitted in the US and around the world beginning in H2 2012 seeking approval for use in men with CRPC who have not yet received...
London, UK, 20 February 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the Citi Global Health Care Conference in New York, US on Tuesday,...
London, UK, 14 February 2012 BTG plc (LSE: BGC), the specialist healthcare company, announces that Rolf Soderstrom will no longer be leaving the company at the end of March and will continue in...
London, UK, 30 January 2012 Study meets all primary, secondary and tertiary endpoints BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-2, the...
London, UK, 25 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today publishes its interim management statement for the period from 1 October 2011 to 24 January 2012. Trading...
London, UK, 18 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that it has received regulatory approval from the US Food and Drug Administration (FDA) for its...
London, UK, 11 January 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the 30th Annual J.P. Morgan Conference on Wednesday 11 January at...